Recent News

• 02.11.2026 - BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting
• 02.05.2026 - BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
• 02.05.2026 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.23.2026 - BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
• 01.12.2026 - BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range
• 01.06.2026 - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.06.2026 - BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference

Recent Filings

• 02.12.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.09.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 01.27.2026 - 3 Initial statement of beneficial ownership of securities
• 01.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.23.2026 - 8-K Current report
• 01.23.2026 - 8-K/A Current report
• 01.23.2026 - EX-99.1 EX-99.1
• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 01.09.2026 - 3 Initial statement of beneficial ownership of securities